Ulixes Capital
VC Fund
Milan, Italy
Ulixes Capital is a venture capital investment firm.
- Total investments:
- 5
- Last investment:
- Lead investor:
- 20%
Last updated:
For AI agents: llms.txt
Industries Ulixes Capital invests in
Stages Ulixes Capital invests in
Countries Ulixes Capital invests in
Round sizes
Round size
- Seed
- $629k–$3.8M
- Pre-Seed
- $1.2M–$1.3M
Investment Focus
Industry
- Health Care 2 (40%)
- EdTech 1 (20%)
- E-Commerce 1 (20%)
- Therapeutics 1 (20%)
- Biotechnology 1 (20%)
Stage
- Seed 2 (40%)
- Pre-Seed 2 (40%)
- Convertible Note 1 (20%)
Country
- Italy 4 (80%)
- Estonia 1 (20%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Flashka guides students through their whole exam preparation. It supports understanding the materials with a chatbot, memorization with AI-generated flashcards, and testing by providing quizzes. Our students experience more efficiency and increase the quality of their study sessions - making them feel confident and ready for exams. | $1.2M / Pre-Seed / Jan 12, 2026 | ||
| Hypesound is revolutionizing the fermentation industry with its innovative sound wave technology. The company is utilizing sonic technology to boost the productivity of algae, yeast, and bacteria, paving the way for sustainable bioproduction and the next industrial revolution. | $1.3M / Pre-Seed / Mar 24, 2025 | ||
| Foreverland Food is an Italian food-tech startup. | $3.8M / Seed / Oct 01, 2024 | ||
| This Unique offers innovative solutions for feminine hygiene needs in both the B2C and B2B sectors. For consumers, we provide convenient subscription boxes delivering eco-friendly menstrual products right to their doorstep, ensuring they have access to high-quality essentials whenever they need them. In the B2B realm, we specialize in installingstate-of-the-art dispensers in corporate restrooms, offering businesses a hassle-free way to provide their employees with complimentary menstrual products. Our mission is to promote sustainability, inclusivity, and well-being, both at home and in the workplace. | $547.6K / Convertible Note / Mar 13, 2024 | ||
| Biovitae focuses on patent development in infection control and prevention, aiming to translate scientific discoveries into practical applications for human health and quality of life. | $628.7K / Seed / Jun 30, 2022 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Ulixes Capital invest in?
Ulixes Capital invests primarily in Health Care, EdTech and E-Commerce startups, most often at Seed and Pre-Seed stage. Most of the 5 investments tracked by Shizune back companies in Italy. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Ulixes Capital's check size?
Ulixes Capital typically joins rounds of $629k–$3.8M at Seed and $1.2M–$1.3M at Pre-Seed. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Ulixes Capital participates in.
When did Ulixes Capital last invest?
The most recent investment recorded for Ulixes Capital closed in Jan 2026. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
